Microalbuminuria reduction with telmisartan in normotensive and hypertensive Japanese patients with type 2 diabetis: A post-hoc analysis of the Incipient to Overt: Angiotensin II Blocker, Telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION) study

Hypertension Research

Volumn 31, Issue 4, 2008, Pages 657-664

  Makino, Hirofumi ^a   Haneda, Masakazu ^b   Babazono, Tetsuya ^c   Moriya, Tatsumi ^d   Ito, Sadayoshi ^e   Iwamoto, Yasuhiko ^c   Kawamori, Ryuzo ^f   Takeuchi, Masahiro ^g   Katayama, Shigehiro ^h  

^a OKAYAMA UNIVERSITY   (Japan)

^b ASAHIKAWA MEDICAL COLLEGE   (Japan)

^c TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^d KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^f JUNTENDO UNIVERSITY   (Japan)

^g KITASATO UNIVERSITY   (Japan)

^h SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Albuminuria; Telmisartan; Type 2 diabetes

Indexed keywords

ALBUMIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; INSULIN; PLACEBO; POTASSIUM SPARING DIURETIC AGENT; TELMISARTAN;

ADULT; ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; CONNECTIVE TISSUE DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DIABETIC PATIENT; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EYE DISEASE; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; HYPERTENSION; INFECTION; INFESTATION; INJURY; JAPANESE; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MUSCULOSKELETAL DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; POST HOC ANALYSIS; RANDOMIZED CONTROLLED TRIAL; REMISSION; SKIN DISEASE; SOFT TISSUE DISEASE; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ALBUMINURIA; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BENZIMIDAZOLES; BENZOATES; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; FEMALE; HUMANS; HYPERTENSION, RENAL; JAPAN; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 44649162402     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1291/hypres.31.657     Document Type: Article

References (28)

1. Makino H, Nakamura Y, Wada J: Remission and regression of diabetic nephropathy. Hypertens Res 2003; 26: 515-519.
2. de Zeeuw D, Remuzzi G, Parving HH, et al: Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 2004; 110: 921-927.
3. Mori H, Ukai H, Yamamoto H, et al: Current status of anti-hypertensive prescription and associated blood pressure control in Japan. Hypertens Res 2006; 29: 143-151.
4. Ruggenenti P, Fassi A, Ilieva AP, et al: Preventing micro-albuminuria in type 2 diabetes. N Engl J Med 2004; 351: 1941-1951.
5. Viberti G, Mogensen CE, Groop LC, Pauls JF: Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. European Microalbuminuria Captopril Study Group. JAMA 1994; 271: 275-279.
6. Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Amer P, Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-878.
7. Ogawa S, Takeuchi K, Mori T, Nako K, Tsubo Y, Ito S: Effects of monotherapy of temocapril or candesartan with dose increments or combination therapy with both drugs on the suppression of diabetic nephropathy. Hypertens Res 2007; 30: 325-334.
8. Viberti G, Wheeldon NM: Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002; 106: 672-678.
9. Sasso FC, Carbonara O, Persico M, et al: Irbesartan reduces the albumin excretion rate in microalbuminuric type 2 diabetic patients independently of hypertension: a randomized double-blind placebo-controlled crossover study. Diabetes Care 2002; 25: 1909-1913.
10. Zandbergen AA, Baggen MG, Lamberts; SW, Bootsma AH, de Zeeuw D, Ouwendijk RJ: Effect of losartan on microalbuminuria in normotensive patients with type 2 diabetes mellitus. A randomized clinical trial. Ann Intern Med 2003; 139: 90-96.
11. Prasad P, Tiwari AK, Kumar KM, et al: Chronic renal insufficiency among Asian Indians with type 2 diabetes: I. Role of RAAS gene polymorphisms. BMC Med Genet 2006; 7: 42.
12. Chandie Shaw PK, Baboe F, van Es LA, et al: South-Asian type 2 diabetic patients have higher incidence and faster progression of renal disease compared with Dutch-European diabetic patients. Diabetes Care 2006; 29: 1383-1385.
13. Hirose T, Kawamori R: Diabetes in Japan. Curr Diab Rep 2005; 5: 226-229.
14. Parving HH, Lewis JB, Ravid M, Remuzzi G, Hunsicker LG, DEMAND investigators: Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective. Kidney Int 2006; 69: 2057-2063.
15. Hollenberg NK: Higher incidence of diabetic nephropathy in type 2 than in type 1 diabetes in early-onset diabetes in Japan. Curr Hypertens Rep 2001; 3: 177.
16. Buse JB, Ginsberg HN, Bakris GL, et al: Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation 2007; 115: 114-126.
17. Khan NA, McAlister FA, Rabkin SW, et al: The 2006 Canadian Hypertension Education Program recommendations for the management of hypertension: Part II - Therapy. Can J Cardiol 2006; 22: 583-593.
18. Japanese Society of Hypertension: Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2004). Hypertens Res 2006; 29 (Suppl): S1-S105.
19. Chobanian AV, Bakris GL, Black HR, et al: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560-2572.
20. O'Hare P, Bilbous R, Mitchell T, O'Callaghan CJ, Viberti GC, ACE-Inhibitor Trial to Lower Albuminuria in Normotensive Insulin-Dependent Subjects Study Group: Low-dose ramipril reduces microalbuminuria in type 1 diabetic patients without hypertension: results of a randomized controlled trial. Diabetes Care 2000; 23: 1823-1829.
21. Parving HH, Hommel E, Jensen BR, Hansen HP: Long-term beneficial effect of ACE inhibition on diabetic nephropathy in normotensive type 1 diabetic patients. Kidney Int 2001; 60: 228-234.
22. Makino H. Haneda M, Babazono T, et al: The telmisartan renoprotective study from incipient nephropathy to overt nephropathy - rationale, study design, treatment plan and baseline characteristics of the Incipient to Overt: Angiotensin II Receptor Blocker, Telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION) Study. J Int Med Res 2005; 33: 677-686.
23. Makino H, Haneda M, Babazono T, et al: Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. Diabetes Care 2007; 30: 1577-1578.
24. Bakris GL, Weir MR, Shanifar S, et al: Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study. Arch Intern Med 2003; 163: 1555-1565.
25. Casas JP, Chua W, Loukogeorgakis S, et al: Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 2005; 366: 2026-2033.
26. Rossing K, Schjoedt KJ, Jensen BR, Boomsma F, Parving HH: Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and inicroalbuminuria. Kidney Int 2005; 68: 1190-1198.
27. Ibsen H, Olsen MH, Wachtell K, et al: Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension 2005; 45: 198-202.
28. Barnett AH, Bain SC, Bouter P, et al: Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004; 351: 1952-1961.